Fig. 5

Survival of patients after clinical diagnosis according to the genotype regarding the presence of BRCA1/BRCA2 variants. The small grey bars represent the censured data (when despite continuous monitoring of outcome event, the death does not occur within the study duration), and the time of follow-up after clinical diagnosis, since we studied patients diagnosed with cancer 28 years ago and some diagnosed 4 years ago. Conflicting data on pathogenicity refers to VUS and benign variants that were predicted as pathogenic by the in silico tools. BRCA1/BRCA2 pathogenic n = 17, BRCA1/BRCA2 benign and with conflicting data on pathogenicity n = 65, non-BRCA1/BRCA2 n = 12. We did not find any significant difference between the genotypes (Logrank test for trend, p = 0.3439)